Skip to content
type1.science
Phase 2RecruitingNCT06688331

Tregs plus anti-CD20 rituximab in pediatric stage 1 T1D

PolTREG phase 2 pediatric prevention trial testing expanded regulatory T cells, rituximab, their combination, or control in children with stage 1 type 1 diabetes to delay progression to dysglycemia.

Primary endpoints

  • Days from treatment to first dysglycemia (stage 2 T1D) through 60 months
  • Adverse events through 60 months

Results so far

No results posted yet.